| |
Jamie Grooms-Chairman, Co-Founder
Jamie M. Grooms has extensive experience launching, growing, and managing biotechnology companies. He leads the AxoGen team by providing business strategy and partnership expertise. He provided the initial seed funding for the corporation. Jamie was the Co-Founder and former CEO of Regeneration Technologies (now RTI Biologics, NASDAQ: RTIX), inventing the primary value-added technologies that formed the basis of RTI’s product line. Jamie led the company through initial venture capital fundraising and an initial public offering in 2000, raising $75 million in proceeds. He has extensive experience in all areas of operation of the allograft business, working at the Virginia Tissue Bank (now LifeNet), Osteotech, and CryoLife in various positions of leadership. From 1992-1998, Jamie served as Director of the University of Florida Tissue Bank. He holds a BS in Biology from Old Dominion University.
 |
Ernest A. Carabillo, Jr., J.D.
Ernest Carabillo is the founder of EXPERTech. He is an internationally recognized authority on regulatory, clinical, and quality management. Previously, he was Vice President of Corporate Regulatory and Quality Administration for Baxter Healthcare Corporation. Prior to that, he was a Management Board Member at Dade Diagnostics, C.R. Bard’s implant and critical care divisions, and the Medical Device and Pharmaceutical Divisions of Union Carbide. In government, he served as the Associate Director for Regulatory Affairs of the Office of Drug Abuse Policy in the executive office of the President, prior to which he held positions in the Department of Justice (DOJ) and the Food and Drug Administration, serving as the Chief of three divisions. He is a member of the New York State Bar and is admitted to appear before all courts in a professional manner including the Supreme Court. He is also a pharmacist.
|
Joe Mandato
Joe Mandato is a general partner and managing director of De Novo Ventures, a venture firm investing in the life sciences. Prior to De Novo, he was an entrepreneur and served as the chief executive of several health care companies. He was Chairman of Confer Software, a developer of software used to create efficiencies and streamline processes in healthcare. He was CEO of ACompany Orthodontics; President/CEO of Origin Medsystems, a developer of minimally invasive surgical devices for use in general, cardio-thoracic, and ob-gyn surgery; a co-founder and CEO of Gynecare, a women’s health spin-out of Origin. Origin was acquired by Guidant Corporation, where Joe served as a vice-president and member of the founding management committee and CEO of two of its five operating units, Origin and Heart Rhythm Technology. Earlier, he founded and was CEO of Ioptex Research, a developer of intraocular lenses used in cataract surgery. He joined Ioptex from Cilco AG in Zug, Switzerland, the Europe, Middle East, and Africa headquarters of a unit of Rorer Group. He began his career in healthcare as a Captain in the U.S. Army Medical Services Corps. He received his doctorate in management from Case Western Reserve University.
|
Gerard van Hamel Platerink
Gerard van Hamel Platerink is a Managing Director with Accuitive Medical Ventures (AMV). Prior to joining Accuitive, Gerard worked at Novoste Corporation, the cardiovascular brachytherapy company, in business development and corporate communications. Before joining Novoste, Gerard was in the Healthcare Group of Salomon Smith Barney in London, where he focused on investments and transactions in the medical device sector. He began his career with Kleinwort Benson, where he was an investment banker and member of the bank’s private equity and mezzanine finance group. Gerard has a BS in Physics from St. Andrews University and an MBA from Cambridge University. Gerard currently serves on the boards of AxoGen Inc., Neuronetics, NeoVista, WaveTec and AqueSys.
|
John Harper
John Harper has extensive leadership experience in the medical device industry. He was President and CEO of ATI Medical, Executive Chairman of Meretekdiagnostics, Inc. (Meretek merged with Diasorin, a division of American Standard Companies), President and CEO of Indigo Medical, Inc., (Indigo merged with Ethicon EndoSurgery, a division of J&J) and was President and CEO of Menlo Care, Inc. (Menlo Care merged with Johnson & Johnson Medical, a division of J&J). He has also served as an Independent Board Member for numerous medical device companies. He began his career in the medical device business with Physio Control Corporation in sales and sales management. John received his BA in Economics from Davidson College.
|
Mark Gold, M.D.
Dr. Mark Gold is a Distinguished Professor and chair at the University of Florida College of Medicine Department of Psychiatry McKnight Brain Institute. Dr. Gold has been a pioneer in translational neuroscience research, from bench to bedside for over three decades. Dr. Gold has combined academic achievement with business and management expertise in a successful career in medicine, academics and finance. Dr. Gold has consulted for companies such as Medtronic, Ciba-Geigy, Sandoz, Boerhinger- Ingelheim, Merck, Wyeth, Roche, Alkermes, Dupont, Glaxo, Abbott, and Forest Laboratories as well as top-tier financial firms such as Goldman Sachs, Lehman Brothers, Oppenheimer, Smith Barney and currently the Carlyle Group. He is a researcher and inventor who has been awarded numerous patents some of which have radically changed medical hypotheses and therapy. He is the author of over 900 scientific research articles, chapters, and abstracts on a wide variety of research subjects. He is frequently the expert interviewed for comment by the Wall Street Journal, other major business, and national publications concerned with the strengths and limitations of new technology and treatments.
|
Norman Weldon
Norman Weldon's background is in economics, technology and general management. He has been the CEO of three public companies: CTS Corporation (NYSE CTS), Cordis Corporation (NASDAQ CORD) and Corvita Corporation (NASDAQ CVTA). He has been a co-founder of CTS Microelectronics, Inc., Corvita Corporation, Novoste Puerto Rico, Inc., Novoste Corporation, Enable Medical Corporation, AtriCure, Inc., Medivance, Inc. and Neuronetics, Inc.
|
| |
|
 |
| |
|
| |
AxoGen Announces U.S. Market Launch of AxoGuard® Nerve Protector and AxoGuard® Nerve Connector to Treat Peripheral Nerves.
More
Axogen assumes full distribution rights for Avance® Nerve Graft.
More |
|
|
